{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Head+Neck+Cancer+Squamous+Cell+Metastatic&page=21", "query": { "condition": "Head Neck Cancer Squamous Cell Metastatic", "page": 21 }, "page_size": 10 }, "pagination": { "page": 21, "page_size": 10, "total_count": 598, "total_pages": 60, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Head+Neck+Cancer+Squamous+Cell+Metastatic&page=22&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Head+Neck+Cancer+Squamous+Cell+Metastatic&page=20&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-27T22:25:26.831Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT07768189", "title": "A Study to Evaluate CRB-701 Compared to Investigator's Choice Therapy in Previously Treated Oropharyngeal Squamous Cell Carcinoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Oropharyngeal Carcinoma (OPC)" ], "interventions": [ { "name": "CRB-701", "type": "DRUG" }, { "name": "capcitabine", "type": "DRUG" }, { "name": "Cetuximab (EGFR inhibitor)", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Corbus Pharmaceuticals Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 260, "start_date": "2026-09-29", "completion_date": "2029-03", "has_results": false, "last_update_posted_date": "2026-10-08", "last_synced_at": "2026-10-27T22:25:26.831Z", "location_count": 38, "location_summary": "Huntsville, Alabama • Tucson, Arizona • Duarte, California + 32 more", "locations": [ { "city": "Huntsville", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07768189" }, { "nct_id": "NCT07602842", "title": "A Study of IDP-001 in Advanced or Metastatic Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Solid Tumor", "Metastatic Solid Tumor", "Head and Neck Squamous Cell Carcinoma", "Cutaneous Squamous Cell Carcinoma", "Squamous Cell Carcinoma of the Cervix", "Non Squamous Non Small Cell Lung Cancer", "Squamous Cell Carcinoma of the Esophagus", "Squamous Cell Carcinoma of the Anus", "Squamous Cell Carcinoma" ], "interventions": [ { "name": "IDP-001", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "InduPro, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 132, "start_date": "2026-07-08", "completion_date": "2028-12", "has_results": false, "last_update_posted_date": "2026-09-03", "last_synced_at": "2026-10-27T22:25:26.831Z", "location_count": 6, "location_summary": "Los Angeles, California • Sarasota, Florida • Indianapolis, Indiana + 3 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Sarasota", "state": "Florida" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Buffalo", "state": "New York" }, { "city": "Lake Success", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT07602842" }, { "nct_id": "NCT00003565", "title": "Docetaxel in Treating Patients With Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Bladder Cancer", "Breast Cancer", "Head and Neck Cancer", "Lung Cancer", "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "docetaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Alliance for Clinical Trials in Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 109, "start_date": "1998-09", "completion_date": "2008-01", "has_results": false, "last_update_posted_date": "2016-07-14", "last_synced_at": "2026-10-27T22:25:26.831Z", "location_count": 72, "location_summary": "Anniston, Alabama • La Jolla, California • San Diego, California + 52 more", "locations": [ { "city": "Anniston", "state": "Alabama" }, { "city": "La Jolla", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003565" }, { "nct_id": "NCT04881045", "title": "Study to Test the Safety and Tolerability of PF-07257876 in Participants With Selected Advanced Tumors.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non-Small Cell Lung Cancer", "Squamous Cell Carcinoma of the Head and Neck", "Ovarian Cancer" ], "interventions": [ { "name": "PF-07257876", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 29, "start_date": "2021-08-18", "completion_date": "2023-10-24", "has_results": false, "last_update_posted_date": "2026-06-02", "last_synced_at": "2026-10-27T22:25:26.831Z", "location_count": 39, "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • Fayetteville, Arkansas + 25 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Fayetteville", "state": "Arkansas" }, { "city": "Rogers", "state": "Arkansas" }, { "city": "Springdale", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04881045" }, { "nct_id": "NCT00002507", "title": "Radiation Therapy and Chemotherapy in Treating Patients With Head and Neck Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Carcinoma of Unknown Primary", "Head and Neck Cancer" ], "interventions": [ { "name": "mitomycin C", "type": "DRUG" }, { "name": "porfiromycin", "type": "DRUG" }, { "name": "brachytherapy", "type": "RADIATION" }, { "name": "radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Yale University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "20 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "20 Years to 80 Years" }, "enrollment_count": null, "start_date": "1992-11", "completion_date": "2002-10", "has_results": false, "last_update_posted_date": "2013-07-25", "last_synced_at": "2026-10-27T22:25:26.831Z", "location_count": 1, "location_summary": "New Haven, Connecticut", "locations": [ { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT00002507" }, { "nct_id": "NCT06788990", "title": "FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Metastatic Head and Neck Squamous Cell Carcinoma", "Recurrent Head and Neck Squamous Cell Carcinoma" ], "interventions": [ { "name": "Ficerafusp alfa", "type": "DRUG" }, { "name": "Pembrolizumab (KEYTRUDA®)", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bicara Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 650, "start_date": "2025-01-28", "completion_date": "2029-07", "has_results": false, "last_update_posted_date": "2026-10-02", "last_synced_at": "2026-10-27T22:25:26.831Z", "location_count": 55, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 41 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06788990" }, { "nct_id": "NCT06062420", "title": "A Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants With PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck- GALAXIES H&N-202", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Neoplasms, Head and Neck" ], "interventions": [ { "name": "Dostarlimab", "type": "DRUG" }, { "name": "Belrestotug", "type": "DRUG" }, { "name": "Nelistotug", "type": "DRUG" }, { "name": "Remzistotug", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 316, "start_date": "2023-11-14", "completion_date": "2027-12-31", "has_results": false, "last_update_posted_date": "2026-09-24", "last_synced_at": "2026-10-27T22:25:26.831Z", "location_count": 5, "location_summary": "New Haven, Connecticut • Iowa City, Iowa • St Louis, Missouri + 2 more", "locations": [ { "city": "New Haven", "state": "Connecticut" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Columbus", "state": "Ohio" }, { "city": "Milwaukee", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT06062420" }, { "nct_id": "NCT03575949", "title": "Standard and Delayed FDG PET/CT After Chemoradiation Therapy in Assessing Patients With Metastatic Head and Neck Squamous Cell Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Metastatic Head and Neck Squamous Cell Carcinoma", "Metastatic Malignant Neoplasm in the Spine" ], "interventions": [ { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Fludeoxyglucose F-18", "type": "OTHER" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "OTHER" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 14, "start_date": "2018-06-15", "completion_date": "2024-05-10", "has_results": false, "last_update_posted_date": "2024-05-14", "last_synced_at": "2026-10-27T22:25:26.831Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03575949" }, { "nct_id": "NCT00011778", "title": "PS-341 and Radiation to Treat Advanced Cancer of the Head and Neck", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Squamous Cell Carcinoma" ], "interventions": [ { "name": "bortezomib", "type": "DRUG" }, { "name": "radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 25, "start_date": "2001-02-22", "completion_date": "2013-02-08", "has_results": false, "last_update_posted_date": "2019-12-12", "last_synced_at": "2026-10-27T22:25:26.831Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00011778" }, { "nct_id": "NCT07227168", "title": "A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Head and Neck Squamous Cell Carcinoma HNSCC", "Non-Small Cell Lung Cancer NSCLC", "Esophageal Cancer", "Gastric Cancer", "Colorectal Cancer", "Pancreatic Ductal Adenocarcinoma (PDAC)", "Cervical Cancer", "Endometrial Cancer", "Urothelial Cancer" ], "interventions": [ { "name": "STRO-004", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sutro Biopharma, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 200, "start_date": "2025-11-07", "completion_date": "2028-04", "has_results": false, "last_update_posted_date": "2026-08-27", "last_synced_at": "2026-10-27T22:25:26.831Z", "location_count": 9, "location_summary": "San Diego, California • Denver, Colorado • Washington D.C., District of Columbia + 6 more", "locations": [ { "city": "San Diego", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Sarasota", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT07227168" } ] }